Interactive Features

Quiz

Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma

03/21/2024

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Did belzutifan improve the time...

03/21/2024

Oncology

Quiz

Quiz: Post-Surgery Everolimus for High-Risk Renal Cell Carcinoma

09/02/2022

In the phase 3 EVEREST trial which looked at everolimus after surgery in patients with high-risk renal cancer, which patients saw the greatest benefit in recurrence-free survival with everolimus?

In the phase 3 EVEREST trial...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Which Study Yields Notable Benefit in Kidney Cancer?

04/15/2021

Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...

Which study reported OS results...

04/15/2021

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Received FDA Approval for Treatment of Advanced RCC?

02/02/2021

Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?

Which combo therapy regimen was...

02/02/2021

Oncology

Test Your Knowledge

Quiz: Which Therapy Had Higher Safety, OS in Papillary RCC?

10/13/2020

Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?

Which therapy had a better...

10/13/2020

Oncology

Test Your Knowledge

Quiz: Is Pembrolizumab Plus Bevacizumab Beneficial for Metastatic RCC?

09/02/2020

True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.

True or False: Pembrolizumab...

09/02/2020

Oncology

Test Your Knowledge

Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?

07/31/2020

True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.

True or false: Ipilimumab plus...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?

10/01/2019

True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.

True or False: Combining...

10/01/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology